Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas

Cancer Discov. 2021 Jan;11(1):20-22. doi: 10.1158/2159-8290.CD-20-1328.

Abstract

In this issue, Kamata-Sakurai and colleagues describe an agonist antibody to CD137 (4-1BB) that takes on an active conformation in environments with high ATP concentrations, characteristic of tumors. This represents a novel advancement in developing immunotherapies that can be administered systemically, but act locally to induce antitumor immune responses without the usual attendant toxicities.See related article by Kamata-Sakurai et al., p. 158.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adenosine Triphosphate*
  • Antibodies, Monoclonal
  • Humans
  • Immunotherapy
  • Neoplasms* / therapy
  • Tumor Necrosis Factor Receptor Superfamily, Member 9

Substances

  • Antibodies, Monoclonal
  • Tumor Necrosis Factor Receptor Superfamily, Member 9
  • Adenosine Triphosphate